Synlogic, Inc., formerly known as "Mirna Therapeutics, Inc.", was established in Delaware in late 2007. The company is a clinical-stage biopharmaceutical company focused on advancing its drug discovery and development platform for synthetic biopharmaceuticals, which is designed to utilize synthetic biology to genetically reprogram beneficial microorganisms to treat metabolic and inflammatory diseases as well as cancer. Synthetic biopharmaceuticals are generated from proprietary drug discovery and development platforms, applying the principles and tools of synthetic biology to design beneficial probiotics to perform or provide critical therapeutic functions. 

SYBX

SYBX Profile